Opzelura patent?

Opzelura is the brand name for topical ruxolitinib (a JAK1/JAK2 inhibitor) used on the skin for conditions like vitiligo. The product is protected by multiple patent families covering:

- The active ingredient (ruxolitinib)
- Topical formulations/creams
- Methods of use (e.g., treating vitiligo and related skin conditions)

Exact patent status and expiration dates depend on the jurisdiction and the particular patent family. In many regions, notable patents may run into the 2030s, but term extensions, pediatric exclusivity, and regional filings can change the dates.

If you’d like, I can look up current, region-specific patent data and give you:
- patent numbers in the US, EU, etc.
- expiration dates and any term extensions or pediatric exclusivity
- links to the patent family records (Google Patents, Espacenet, USPTO)

Please tell me which region you care about (e.g., United States, European Union) and whether you want the composition-of-matter patents, formulation patents, or method-of-use patents.